Stevens Institute of Technology Opens Biotechnology and Drug–Discovery Laboratory
The Stevens Institute of Technology will open a new biotechnology laboratory in January 2014.
The Center for Healthcare Innovation at Stevens Institute of Technology will open its Biotechnology and Drug-Discovery Laboratory in January 2014 as a new biotechnology and drug discovery enterprise that will partner with other Stevens faculty, students, and external academic and industry collaborators. Established in part with a donation of equipment and supplies from Hoffmann-La Roche and support from the New Jersey Department of Labor, seven former Roche personnel recently joined Stevens as faculty and researchers in this new initiative. Laboratory staff also includes three new professors with R&D experience in pharmaceutical and biotechnology corporate laboratories. The laboratory will serve as a center for research in the areas of preclinical gene cloning and purification of therapeutic proteins, assay development, and robotic drug screening.
Source: Stevens Institute of Technology
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
